Delivering clarity
for a better tomorrow.

PROSTATENOW™ is a comprehensive germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.

Why should urologists consider PROSTATENOW™ ?

Who benefits from PROSTATENOW™ ?

How do urologists incorporate PROSTATENOW™ into their practice?

Family History (FH)

FH is a common but indirect measurement of inherited risk.

Men with a positive FH have a 1.5-to-2.5-fold increased risk for developing prostate cancer.

Rare Pathogenic Mutations (RPMs)

RPMs are pathogenic DNA mutations in the coding regions of genes such as BRCA2, ATM, and CHEK2.

RPMs are associated with a moderate-to-high risk for developing prostate cancer. Also associated with prostate cancer aggressiveness.

Genetic Risk Score (GRS)

Calculated based on more than 100 single nucleotide polymorphisms (SNPs) associated with prostate cancer risk.

Used to assess a man’s risk of developing prostate cancer compared to other men in the general population.

Assess prognosis for localized prostate cancer patients

Information on RPMs can supplement traditional clinical variables such as Gleason Score and PSA levels to predict disease progression and inform personalized decisions on prostate cancer treatment such as pursuing active surveillance vs. definitive treatment with either surgery or radiation.

Recommends therapeutic responses for advanced prostate cancer patients

RPMs in DNA repair genes and other genes can complement clinical variables and somatic DNA testing when making a personalized decision on drug treatments.

Assess risk for unaffected men

Men with RPMs and a higher GRS may evaluate their chances of passing on this risk to their offspring and consider early and more frequent prostate cancer screening. It is important to consider testing for patients who meet guideline recommendations.